- |||||||||| Sulonex (sulodexide) / Alfasigma, Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Review, Journal: Raynaud's Phenomenon with Focus on Systemic Sclerosis. (Pubmed Central) - May 15, 2022
An extensive range of pharmacotherapies with various routes of administration are available for Raynaud's phenomenon but a standardized therapeutic plan is still lacking. This review provides insight into recent advances in the understanding of Raynaud's phenomenon pathophysiology, diagnostic methods, and treatment approaches.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Antibody-induced procoagulant platelets cause increased thrombus formation in heparin-induced thrombocytopenia (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_202;
GFX partially inhibited convulxin-induced aggregation, abolished convulxin-stimulated pS-sites, but increased convulxin-induced Syk/Btk pY-sites. HIT IgG fractions induced significant increase in the formation of CD62P/PS positive procoagulant PLTs compared to buffer and HC IgG (38.87%±1.99 vs. 4.43%±3.25, p=0.001; and vs. 1.43%±0.83, p=0.050, respectively, Figure 1A).
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
IV ILOPROST ! (Twitter) - May 10, 2022
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Tracleer (bosentan) / J&J, Roche
PDE5i, Bosentan or other Endothelin Ant Rc, NTG oilment, Botox, iloprost and sympathectomy (Twitter) - May 7, 2022
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Iloprost (Twitter) - May 7, 2022
- |||||||||| sildenafil / Generic mfg., Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Tracleer (bosentan) / J&J, Roche
Iloprost Bosentan Sildenafil (Twitter) - May 7, 2022
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal, Combination therapy: Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy. (Pubmed Central) - May 7, 2022
During the follow-up RHC, in a comparison of the pre-inhalation and best recorded values out to 30 min after the end of iloprost inhalation, iloprost significantly decreased mPAP (32.5 ± 7.2 to 30.0 ± 6.6 mmHg, p = 0.007) and PVR (457.8 ± 181.4 to 386.2 ± 142.8 dyn s cm, p = 0.025) and significantly increased cardiac output (4.19 ± 0.91 to 4.64 ± 1.01 L/min, p = 0.035). Iloprost may have not only acute vasodilation effects but also long-term hemodynamic benefits in PAH patients receiving combination therapy.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress. (Pubmed Central) - Apr 26, 2022
These findings open new therapeutic avenues to improve HSC engraftment after autologous transplantations by short ex vivo pulse treatment with prostacyclin analogs; and limit loss of HSC and acquired bone marrow failure by protecting HSC in patients undergoing radiation or chemotherapy treatment for non-hematologic malignancies. Prostacyclin analogs are safe, used clinically for vascular diseases, and thus have potential for swift repurposing for the therapies mentioned above.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Prostacyclins and pulmonary arterial hypertension in children. (Pubmed Central) - Apr 8, 2022
Treprostinil is a long-acting prostacyclin analog, and it shows the highest antiproliferative activity among prostacyclins. Beraprost may be effective in premature infants, but available evidence comes from only one patient, so more clinical testing is needed.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Preclinical, Journal: Intranasal iloprost prevents tumors in a murine lung carcinogenesis model. (Pubmed Central) - Apr 5, 2022
Previous pre-clinical studies of iloprost used oral delivery, but a study modeling delivery directly to the target organ was needed. In vivo and in vitro studies have identified gene expression changes following iloprost treatment, including increased E-cadherin and PPAR
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension. (Pubmed Central) - Mar 29, 2022
Inhaled iloprost can improve cardiovascular performance in the presence of PAH, primarily through a reduction in right ventricular afterload and interventricular pressure. Decreased pressure on the interventricular septum and ventricles leads to conduction system normalization including of the AH interval and SNRT due to resolution of inflammation and edema.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: ILOCOVID: Inhaled Iloprost for Suspected COVID-19 Respiratory Failure (clinicaltrials.gov) - Mar 29, 2022
P2, N=40, Completed,
Decreased pressure on the interventricular septum and ventricles leads to conduction system normalization including of the AH interval and SNRT due to resolution of inflammation and edema. Recruiting --> Completed
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Retrospective data, Journal: Management of Severe Scoliosis with Pulmonary Arterial Hypertension: A Single-Center Retrospective Case Series Study. (Pubmed Central) - Mar 25, 2022
The anesthetic management of scoliosis patients with PAH is important task that, like its own surgery, relies on the input of the multidisciplinary team for its success. Close monitoring, optimization of systemic blood pressure, pain control, oxygenation and ventilation, avoidance of exacerbating factors, and the use of vasopressors and pulmonary vasodilators when necessary are essential elements of management.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
A CASE OF ACUTE CHEST SYNDROME RESULTING IN COR PULMONALE RESPONSIVE TO PULMONARY VASODILATORS ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_2555;
There is a paucity of data on the efficacy and mortality benefits of using inhaled pulmonary vasodilators in this setting. However, our case demonstrates safe and effective use of early pulmonary vasodilators, inhaled nitric oxide, and iloprost, in this severely ill patient which was associated with an acceptable outcome.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: A Technology for Anti-Thrombogenic Drug Coating of Small-Diameter Biodegradable Vascular Prostheses. (Pubmed Central) - Mar 17, 2022
The surface of vascular prostheses with heparin and iloprost was resistant to adhesion of platelets and blood proteins. Drug (unfractionated heparin and iloprost) coating of the surface of biodegradable prostheses significantly improved the anti-thrombogenic properties of these grafts but contributed to the increased stiffness of the prostheses.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Uptravi (selexipag) / J&J, Nippon Shinyaku
Binding Affinity of Treprostinil to Rat Recombinant Prostanoid Receptors IP and EP2 (Area K, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_4897;
In contrast, the binding affinity of selexipag was lower in rats compared to humans for both IP and EP2, respectively. This data may provide useful information for interpreting results from rat studies of the prostacyclin prodrug treprostinil palmitil to inform dosage selection for studies in PAH patients.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Iloprost Reverses Bronchial Dysplasia by Improving Airway Progenitor Function, Affecting Cell Metabolism and Dampening inflammation (Room 203-204 (South Building, Level 2), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_2507;
This data may provide useful information for interpreting results from rat studies of the prostacyclin prodrug treprostinil palmitil to inform dosage selection for studies in PAH patients. Iloprost affects energy metabolism of progenitor cells, dampens inflammation, and improves their function, all of which may be critical for its role in improving dysplasia.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Transient multisite Y/S-phosphorylation of Syk and Btk in GPVI-stimulated platelets (hall 1; hall 2; hall 3; hall 4; hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_342;
This points to an important role of PKC phosphorylation in providing feedback inhibition of these tyrosine protein kinases after GPVI-stimulation. As both Syk and Btk are part of the GPVI-induced platelet signalosome, our findings show a novel negative feedback role of PKC isoforms in this signaling complex, which is additionally modulated by PKA.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Upregulation of cAMP prevents antibody-induced procoagulant platelet and thrombus formation in COVID-19 (hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_101;
Our findings indicate that COVID-19 Abs are harbouring the potential to induce procoagulant PLTs and increased thrombus formation via the engagement of PLT FcγRIIA. The observation that Ab-induced procoagulant PLTs and increased thrombus formation were significantly inhibited in the presence of Iloprost might direct towards a therapeutic potential of cAMP upregulators in the treatment of the severe coagulation disorder observed in critical ill COVID-19 patients.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Review, Journal: Inhaled Pharmacotherapy for Neonates: A Narrative Review. (Pubmed Central) - Feb 4, 2022
Information is given on several inhaled drugs, namely albuterol, budesonide, ipratropium bromide, sodium cromoglycate, racemic epinephrine, nitric oxide, treprostinil, iloprost, epoprostenol, colistin, rhDNase, hypertonic saline, and calfactant. A summary of the main and most recent published studies on each of these inhaled pharmacological agents is also presented.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
Octopus Toes? () - Jan 30, 2022 - Abstract #BSR2022BSR_315;
It is most common in older females. The cause is not clear, but the predominant hypothesis is that a catecholamine surge leads to microvascular spasm and myocardial stunning.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. (Pubmed Central) - Jan 29, 2022
Intravenous prostacyclin-analogs (PCA, e.g. epoprostenol, treprostinil, iloprost) have become an essential part in the therapy of patients with pulmonary hypertension (PH), mainly pulmonary arterial hypertension (PAH)...Preliminary data suggest that selected patients could benefit from an "upfront triple" therapy. Controlled studies on which such recommendation could be based are lacking.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Inhibitory Potentiality of Secondary Metabolites Extracted from Marine Fungus Target on Avian Influenza Virus-A Subtype H5N8 (Neuraminidase) and H5N1 (Nucleoprotein): A Rational Virtual Screening. (Pubmed Central) - Jan 26, 2022
In case of drug prediction, the study recommends Estramustine and Iloprost against both nucleoprotein and neuraminidase. Besides these, Butorphanol, Desvenlafaxine, Zidovudine and Nadolol are the best drug candidates for nucleoprotein inhibitors, meanwhile, Sitaxentan, Ergoloid mesylate, Capecitabine and Fenoterol act as speculated candidates against neuraminidase.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change, Trial termination: OVATION: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (clinicaltrials.gov) - Jan 26, 2022
P4, N=27, Terminated,
Besides these, Butorphanol, Desvenlafaxine, Zidovudine and Nadolol are the best drug candidates for nucleoprotein inhibitors, meanwhile, Sitaxentan, Ergoloid mesylate, Capecitabine and Fenoterol act as speculated candidates against neuraminidase. N=50 --> 27 | Recruiting --> Terminated; slow enrollment
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. (Pubmed Central) - Jan 15, 2022
Most importantly, antibody-induced procoagulant events as well as increased thrombus formation in severe COVID-19 were inhibited by Iloprost a clinically approved therapeutic agent that increases the intracellular cAMP levels in PLTs. Our data indicate that upregulation of cAMP could be a potential therapeutic target to prevent antibody-mediated coagulopathy in COVID-19 disease.
|
